Newsroom | 31710 results

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, highlights activity at recent scientific conferences and announces participation in future events. Highlights include: March 12, 2025 – Presented at the Society for Immunotherapy of Cancer Spring Scientific Meeting titled, “Novel GITR Agonist KROS 101: A Dual Approach to Boost T Cell Immunity and Alter the Tumor Microenvironment” March 17 to 19 – Participated in the BIO Europe co...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug...

LIESTAL, Svizzera--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, "Curatis") comunica un fatturato di 6,9 milioni di CHF per il 2024, in cui Curatis AG è inclusa solo per un periodo di 8 mesi. Curatis AG è stata in grado di aumentare le vendite dell'attività di distribuzione del 30%, raggiungendo 9,5 milioni di CHF nell'intero anno 2024 rispetto al 2023. Ulteriori dichiarazioni chiave: Curatis sta aumentando di 20 volte la stima del numero di pazienti trattati nell'ambito del progetto principal...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as “subcutaneous pembrolizumab”). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today...

STOCKHOLM--(BUSINESS WIRE)--France’s restrictive stance on safer alternatives to cigarettes threatens to derail efforts to reduce the deadly toll of tobacco, according to major new research by international health experts. Their study, Tale of Two Nations: France vs Sweden, contrasts the tobacco control policies of the two countries and highlights how Sweden’s embrace of harm reduction strategies has resulted in the lowest smoking rates in Europe, while more than one in four French adults smoke...

WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test. NavDx+Gyn is a cell-free DNA-based fragmentomic profiling assay that enhances the detection and monitoring of human papillomavirus (HPV)-driven gynecologic cancers. Leveraging the robust foundation of the NavDx test, which has been validated in over 35 peer-reviewed publica...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial Highlights Revenue of Orelabrutinib increased by 49.1% to RMB 1,000.4 million1 in 2024, mainly driven by rapid growth of marginal zone lymphoma (MZL) indication and strong commercial execution. Total revenue increased by 36.7% to RMB 1,009.4 million in 2024. Gross Profit inc...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) of its operating company Fresenius Kabi, has been approved by the U.S. Food and Drug Administration (FDA). These denosumab biosimilars are approved for all indications of the reference products: Prolia® (denosumab) and Xgeva® (denosumab), respectively. In addition, the Fresenius operating company has reache...

BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative therapies for prevention and treatment of breast cancers, announces the filing of a new provisional patent application directed to the use of HAV-088 for treating Ductal Carcinoma In-Situ. Backed by human in vivo data demonstrating on-target effect, the patent application covers the potential application of HAV-088, a novel androgen receptor (AR) agonist, in treating hormone rec...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging Institute). This agreement aims to develop new technologies to enable researchers to better visualize human cells, significantly advancing scientific research and discovery. Cryo-electron microscopy (cryo-EM) is an essential tool in disease research and creating lifesaving...